Literature DB >> 8840971

Differential expression of psoriasin messenger RNA between in situ and invasive human breast carcinoma.

E Leygue1, L Snell, T Hiller, H Dotzlaw, K Hole, L C Murphy, P H Watson.   

Abstract

The mRNA encoding the calcium-binding protein psoriasin was identified as being more highly expressed in the in situ versus the invasive component of the same breast tumor. Reverse transcription-PCR analysis of total RNA extracted from three independent cases of ductal carcinoma in situ of the comedo type and three cases of high-grade invasive ductal carcinoma revealed a detectable level of psoriasin mRNA expression in the in situ lesions only. Similar analysis performed on total RNA extracted from frozen sections of 32 independent breast samples, representing a continuum from normal to invasive tumor, confirmed high psoriasin expression in ductal carcinoma in situ of the comedo type only. The possible functional role of the psoriasin protein in breast tumor cells remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8840971

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

1.  Psoriasin (S100A7) expression and invasive breast cancer.

Authors:  S Al-Haddad; Z Zhang; E Leygue; L Snell; A Huang; Y Niu; T Hiller-Hitchcock; K Hole; L C Murphy; P H Watson
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

2.  Tumor-suppressive effects of psoriasin (S100A7) are mediated through the β-catenin/T cell factor 4 protein pathway in estrogen receptor-positive breast cancer cells.

Authors:  Yadwinder S Deol; Mohd W Nasser; Lianbo Yu; Xianghong Zou; Ramesh K Ganju
Journal:  J Biol Chem       Date:  2011-10-20       Impact factor: 5.157

3.  Knockdown of S100A7 reduces lung squamous cell carcinoma cell growth in vitro and in vivo.

Authors:  Guijuan Liu; Qiang Wu; Guilan Liu; Xueying Song; Jihong Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

4.  S100A7 has an oncogenic role in oral squamous cell carcinoma by activating p38/MAPK and RAB2A signaling pathway.

Authors:  K K Dey; R Bharti; G Dey; I Pal; Y Rajesh; S Chavan; S Das; C K Das; B C Jena; P Halder; J G Ray; I Kulavi; M Mandal
Journal:  Cancer Gene Ther       Date:  2016-10-21       Impact factor: 5.987

5.  Psoriasin (S100A7) is significantly up-regulated in human epithelial skin tumours.

Authors:  Noemi Moubayed; Michael Weichenthal; Jürgen Harder; Elke Wandel; Michael Sticherling; Regine Gläser
Journal:  J Cancer Res Clin Oncol       Date:  2006-11-29       Impact factor: 4.553

6.  Potent genistein derivatives as inhibitors of estrogen receptor alpha-positive breast cancer.

Authors:  Radharani Marik; Madhan Allu; Ravi Anchoori; Vered Stearns; Christopher B Umbricht; Saeed Khan
Journal:  Cancer Biol Ther       Date:  2011-05-15       Impact factor: 4.742

7.  Relationship between mammaglobin expression and estrogen receptor status in breast tumors.

Authors:  Xiao-feng Guan; Mohammad K Hamedani; Adewale Adeyinka; Christina Walker; Angela Kemp; Leigh C Murphy; Peter H Watson; Etienne Leygue
Journal:  Endocrine       Date:  2003-08       Impact factor: 3.633

8.  Structural and functional characterization of a triple mutant form of S100A7 defective for Jab1 binding.

Authors:  Nathan R West; Benjamin Farnell; Jill I Murray; Fraser Hof; Peter H Watson; Martin J Boulanger
Journal:  Protein Sci       Date:  2009-12       Impact factor: 6.725

9.  Highly homologous hS100A15 and hS100A7 proteins are distinctly expressed in normal breast tissue and breast cancer.

Authors:  Ronald Wolf; Christopher Voscopoulos; Jason Winston; Alif Dharamsi; Paul Goldsmith; Michele Gunsior; Barbara K Vonderhaar; Melanie Olson; Peter H Watson; Stuart H Yuspa
Journal:  Cancer Lett       Date:  2009-01-10       Impact factor: 8.679

Review 10.  Opposing functions of psoriasin (S100A7) and koebnerisin (S100A15) in epithelial carcinogenesis.

Authors:  Eva Hattinger; Stephanie Zwicker; Thomas Ruzicka; Stuart H Yuspa; Ronald Wolf
Journal:  Curr Opin Pharmacol       Date:  2013-05-09       Impact factor: 5.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.